Skip to content
Screener

Iovance Biotherapeutics, Inc. IOVA Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$8.72B-30.8%
Gilead Sciences logo
Gilead SciencesGILD
$3.18B-38.2%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$205.19M+238%
CTO
Citius Oncology, Inc.CTOR
$2.63M+2,350,466%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$78.64M+8.0%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$301.92M+944%

Other financials

Income statement

See full
Revenue$99.3M+65.7%
Gross profit$55.7M+403%
Operating income-$51.9M+54.4%
Net income-$47.3M+57.6%
EPS (diluted)-$0.11+66.7%

Balance sheet

See full
Total debt$46.0M-11.8%
Total equity$736.0M+5.4%
Total assets$915.5M+0.9%

Cash flow

See full
Operating cash flow-$60.8M+9.8%
CapEx$5.4M-27.1%
Free cash flow-$66.3M+11.5%

Valuation

See full
Market cap$2.77B+222%
Enterprise value$2.71B+247%
P/S8.5×+5.0×

Profitability

See full
Gross margin48.4%+15.0pp
Operating margin-92.7%-29.0pp
Net margin-89.1%-27.6pp
FCF margin-91.2%-22.1pp

Returns & leverage

See full
Return on equity-40.4%-7.8pp
Debt / equity0.1×0.0×
Current ratio4.3×+1.1×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 9:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091716

FAQ

What is Iovance Biotherapeutics, Inc.'s cash & equivalents?
Iovance Biotherapeutics, Inc. (IOVA) reported cash & equivalents of $110.77M in Q2 2026.
How has Iovance Biotherapeutics, Inc.'s cash & equivalents changed year-over-year?
Iovance Biotherapeutics, Inc.'s cash & equivalents decreased by 16.4% year-over-year, from $132.47M to $110.77M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s cash & equivalents has grown at a 19.4% compound annual growth rate (CAGR), from $67.33M to $163.08M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Iovance Biotherapeutics, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude